<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary hypertension with congenital heart disease: Pregnancy and contraception</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary hypertension with congenital heart disease: Pregnancy and contraception</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary hypertension with congenital heart disease: Pregnancy and contraception</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthias Greutmann, MD, FESC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3060421357"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Approximately 3 to 10 percent of patients with congenital heart disease (CHD) develop pulmonary hypertension (termed pulmonary hypertension-congenital heart disease [PH-CHD]) [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Epidemiology'</a>.)</p><p>For patients with PH-CHD, the maternal and fetal risks of pregnancy, contraception methods, and management of pregnancy are discussed here. The clinical manifestations and diagnosis, general management, and disease-specific management of PH-CHD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: General management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/139770.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: Disease-specific management"</a>.)</p><p class="headingAnchor" id="H2954885224"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension (PH)</strong> – PH is defined as a mean pulmonary artery pressure (PAP) &gt;20 mmHg at rest [<a href="#rid3">3</a>]. This threshold for diagnosis is lower than the previously used threshold of ≥25 mmHg [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary hypertension-congenital heart disease (PH-CHD)</strong> – Patients with PH-CHD have a variety of types of PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>). In patients with PH-CHD, PH is commonly, but not always, caused by CHD. The most common type of PH-CHD is congenital shunt-related pulmonary arterial hypertension (PAH). (See  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Classification'</a> and  <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">"Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary arterial hypertension</strong> – PAH is a type of PH diagnosed by demonstration of a mean PAP ≥20 mmHg and a pulmonary vascular resistance (PVR) ≥2 Wood units (WU), along with exclusion of other types of PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>). In the 2022 European Society of Cardiology/European Respiratory Society guidelines, the definition of PAH was revised to &gt;2 WU (from ≥3 WU) to reflect data regarding the prognostic significance of PVR &gt;2 WU [<a href="#rid5">5,6</a>]. However, for treatment purposes, PVR &gt;3 WU is utilized since data regarding utility of treatment for PVR 2 to 3 WU are not available. Severe PAH is identified by a PVR ≥5 WU [<a href="#rid7">7</a>]. PAH associated with CHD (PAH-CHD) is one of many types of PAH. Eisenmenger syndrome is the most severe form of congenital shunt-related PAH. (See  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 1: Pulmonary arterial hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eisenmenger syndrome</strong> – This disorder is the most severe form of congenital shunt-related PAH and is characterized by the triad of large intra- or extracardiac defect with an initial systemic-to-pulmonary shunt (ventricular, atrial, or great artery  (<a class="graphic graphic_table graphicRef55944" href="/z/d/graphic/55944.html" rel="external">table 2</a>)), PAH with shunt reversal (right-to-left) or bidirectional shunting, and resulting hypoxemia with cyanosis  (<a class="graphic graphic_figure graphicRef52487 graphicRef70502" href="/z/d/graphic/52487.html" rel="external">figure 1A-B</a>) [<a href="#rid8">8,9</a>]. The pulmonary arterial disease in Eisenmenger syndrome is caused by increased pulmonary blood flow and/or elevated PAP.</p><p></p><p class="headingAnchor" id="H1737517343"><span class="h1">RISK OF PREGNANCY</span><span class="headingEndMark"> — </span>Pregnancy in a patient with PH-CHD is associated with high maternal and fetal risks.</p><p class="headingAnchor" id="H4214670351"><span class="h2">Maternal issues</span><span class="headingEndMark"> — </span>The risk of maternal mortality and morbidity with PH-CHD is highest for patients with Eisenmenger syndrome [<a href="#rid10">10</a>]. Risk factors for maternal morbidity and mortality include severity of PH, lower arterial oxygen saturation, higher B-type natriuretic peptide level, pericardial effusion on echocardiography, need for hospitalization, and general anesthesia [<a href="#rid10">10,11</a>].</p><p>Reported maternal mortality with Eisenmenger syndrome appears to be declining but remains high. The rate of maternal mortality in Eisenmenger syndrome ranged from 38 to 50 percent in reports prior to 1996 [<a href="#rid11">11-16</a>], the mean mortality rate was 25 percent for reports during 1997 to 2007 [<a href="#rid11">11</a>], and mortality rates of 23.3 [<a href="#rid17">17</a>], 16.7 [<a href="#rid10">10</a>], and 10.3 [<a href="#rid18">18</a>] percent were reported by studies performed during various time intervals between 2007 and 2019. The mortality risk cannot be reliably predicted in an individual patient with Eisenmenger syndrome, and death can occur even in patients with few symptoms prior to pregnancy [<a href="#rid19">19</a>].</p><p>Even moderate pulmonary vascular disease carries a substantial pregnancy risk since the disease can worsen during pregnancy; thus, no safe cut-off value for pulmonary arterial pressure is known, though risk is likely lower in those with only mildly increased pressure [<a href="#rid19">19</a>]. </p><p>Lower risk in the setting of PAH without Eisenmenger was suggested by a report from Beijing, in which there were no maternal deaths among 51 patients with PAH-CHD with left-to-right shunt, compared with maternal mortality of 7.7 percent for those with persistent PAH-CHD after previous correction of the defect and 16.7 percent for those with Eisenmenger syndrome [<a href="#rid10">10</a>]. The rates of peripartum heart failure and pulmonary hypertensive crisis were 13.7 and 2.0 percent of those with PAH-CHD with left-to-right shunt, 46.2 and 23.1 percent among those with PAH-CHD with a corrected defect, and 66.7 and 20.0 percent among those with Eisenmenger syndrome.</p><p>The majority of maternal deaths occur after delivery during the first week postpartum, but deaths can occur during gestation (particularly the last trimester), labor, or more than one week after delivery [<a href="#rid10">10-13,15,17</a>]. The fixed pulmonary arterial resistance cannot accommodate the hemodynamic fluctuations of labor, delivery, and the puerperium. Most deaths are due to refractory right heart failure, pulmonary hypertensive crisis, thromboembolism, volume depletion (which can augment the right-to-left shunt and precipitate intense cyanosis), and preeclampsia [<a href="#rid12">12-14,19</a>]. When pulmonary hypertensive crisis occurs with sudden increase in pulmonary vascular resistance, right heart failure and systemic hypotension may fatally reduce cerebral blood flow [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H575247694"><span class="h2">Fetal issues</span><span class="headingEndMark"> — </span>In the setting of maternal Eisenmenger syndrome, there is substantial fetal risk because of maternal cyanosis that increases during the course of pregnancy as the fall in systemic vascular resistance enhances the right-to-left shunt. Only 15 to 25 percent of pregnancies progress to term, and at least 50 percent of infants are born prematurely [<a href="#rid11">11-14,16,21</a>]. Spontaneous abortion occurs in 20 to 40 percent of pregnancies, at least 20 to 30 percent of infants born have intrauterine growth retardation, and perinatal mortality has ranged from 7 to 28 percent [<a href="#rid11">11-16</a>].</p><p>In the setting of PH-CHD without Eisenmenger syndrome and cyanosis, limited data suggest that the fetal risk may be lower. In a study from Beijing, there were no fetal deaths among 51 pregnancies with maternal PAH with a left-to-right shunt and 13 pregnancies with maternal PAH after defect correction, compared with fetal mortality of 3.3 percent with maternal Eisenmenger syndrome [<a href="#rid10">10</a>]. Numbers were small, but rates of fetal distress were 2.0 percent among those with PAH and left-to-right shunt, 7.7 percent in those with PAH after defect correction, and 10 percent among those with Eisenmenger syndrome.</p><p>An additional concern in the setting of maternal PH-CHD is the increased risk of CHD in the fetus. In a literature review of studies published between 1985 and 2007, recurrence was noted in 1 of 20 completed (&gt;20 weeks gestation) pregnancies in women with Eisenmenger syndrome [<a href="#rid16">16</a>]. Prenatal screening and diagnosis of CHD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Inheritance'</a> and  <a class="medical medical_review" href="/z/d/html/6755.html" rel="external">"Congenital heart disease: Prenatal screening, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H1172841215"><span class="h1">CONTRACEPTION METHODS</span><span class="headingEndMark"> — </span>Safe and effective contraception options are crucial for PH-CHD patients given the very high risks of pregnancy to both the mother and fetus. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a> and  <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: General management and prognosis", section on 'Pregnancy'</a>.)</p><p>Women with severe PH-CHD, especially those with Eisenmenger syndrome, and their partners should be counseled about the importance of avoidance of pregnancy in view of the high risk of maternal death and should be educated regarding safe and appropriate methods of contraception. Our approach to counseling is informed by the Centers for Disease Control and Prevention's <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=139887" target="_blank">Medical Eligibility Criteria for Contraceptive Use</a>, the European Society of Cardiology (ESC) guidelines for the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Feurheartj%2Farticle%2F39%2F34%2F3165%2F5078465&amp;token=i%2BIJbZ3566jvLjqylaYc8Kl2hE2P5Gw5292rgeNt3TFYJ5OiVyPJdjtJ1FKGT3cHsztGP39zDb1L%2BmDeOtQdyTZ8CHGTnctUb6fDlAZ%2FLrU%3D&amp;TOPIC_ID=139887" target="_blank">management of cardiovascular disease during pregnancy</a>, and established contraceptive failure rates  (<a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">figure 2</a>) [<a href="#rid19">19,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>Options for contraception include male vasectomy, long-acting reversible contraception (LARC), and female sterilization. Vasectomy has a first-year typical-use failure rate of 0.15 percent and is the safest sterilization option as it does not require intraabdominal surgery or general anesthesia [<a href="#rid23">23</a>] When considering vasectomy as a permanent contraception method for the male partner of a female with severe PH-CHD, one consideration is the limited life-expectancy for individuals with severe PH-CHD.</p><p>If vasectomy is declined, then we discuss LARC, including intrauterine devices and the <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">etonogestrel implant</a>, and female sterilization. For women who desire female sterilization, the risks of abdominal surgery, general anesthesia, and pneumoperitoneum need to be weighed against the minimal risks of nonsurgical LARC methods, which have similar efficacy (first-year typical-use failure rates of 0.5 percent for female tubal surgery and 0.1 to 0.8 percent for LARC) [<a href="#rid24">24</a>]. Of note, tubal hysteroscopic sterilization is no longer available. (See  <a class="medical medical_review" href="/z/d/html/8094.html" rel="external">"Vasectomy"</a> and  <a class="medical medical_review" href="/z/d/html/101560.html" rel="external">"Overview of female permanent contraception"</a>.)</p><p>For women who decline permanent sterilization, available LARC methods include levonorgestrel-releasing intrauterine devices and the <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">etonogestrel implant</a>. Of the intrauterine devices, we prefer the 52 mg levonorgestrel-releasing intrauterine devices (IUDs; commercial names Mirena, Liletta) because they reduce menstrual blood loss and result in an approximately 20 percent amenorrhea rate after one year of use. As the <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">copper IUD</a> (commercial name Paragard) is associated with heavier and longer menses, we prefer to avoid this device, particularly in cyanotic women with hematocrit levels above 55 percent, because intrinsic hemostatic defects further increase the risk of excessive menstrual bleeding. An equally effective LARC is the etonogestrel implant. While the etonogestrel implant can cause longer or shorter duration of menstrual bleeding, users generally experience decreased overall menstrual bleeding compared with nonusers, but the pattern is less predictable [<a href="#rid25">25,26</a>]. Some women prefer the upper arm insertion of the etonogestrel implant rather than intrauterine insertion of IUDs. While uncommon, syncope can occur during placement of any of these devices. For this reason, the ESC guidelines advise insertion in a monitored setting, such as an operating room, although supporting data are limited and are based in part on the Lippes Loop IUD, which is no longer in use [<a href="#rid19">19,27</a>].</p><p>Given the high risk of maternal mortality should pregnancy occur, we do not advise use of other less-effective contraceptive methods, including hormonal pills, patches, and rings; injectable contraception; pericoital contraceptives (diaphragm, cervical cap, spermicidal sponge); and barrier contraceptives when used alone (male and female condoms)  (<a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">figure 2</a>). However, some women may elect to combine less-effective contraceptive methods to increase contraceptive efficacy (eg, oral progesterone pills plus a barrier method such as male or female condom).</p><p>Estrogen-containing contraceptives are contraindicated because of the increased risks of hypertension and thromboembolism and resultant risk of paradoxical embolism [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H395324451"><span class="h1">MANAGEMENT OF PREGNANCY</span><span class="headingEndMark"> — </span>As noted above, pregnancy in a patient with PH-CHD<strong> </strong>is associated with high maternal and fetal risks and should be discouraged [<a href="#rid5">5,19</a>]. Careful preconception risk assessment and counseling at a specialist center are recommended.</p><p class="headingAnchor" id="H1790859794"><span class="h2">Counseling if pregnancy occurs</span><span class="headingEndMark"> — </span>Women with PH-CHD who become pregnant should receive individualized counseling regarding maternal and fetal risks from cardiovascular and obstetric caregivers with expertise in the management of PH-CHD. The earliest possible pregnancy termination should be discussed, as termination may be life-saving for the mother. However, termination carries a risk and should only be performed at a care facility that cares for patients with complex PH-CHD.</p><p>Termination in the first trimester appears to be safer than allowing pregnancy continuation. For termination of pregnancy, uterine aspiration (also known as dilation and curettage) in the first trimester is the choice of most experts. Prostaglandin F2 alpha should be <strong>avoided</strong> due to reports of arterial oxygen desaturation in pregnant patients with PH [<a href="#rid28">28</a>]. Second- or third-trimester termination may carry a risk equal to or greater than continuation of pregnancy, but may be reasonable after the risks of termination are balanced against the risks of continuation of pregnancy [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p class="headingAnchor" id="H2539004014"><span class="h2">Management during pregnancy</span><span class="headingEndMark"> — </span>When a patient elects to continue pregnancy, comprehensive multidisciplinary care, including (at a minimum) maternal-fetal medicine, PH-CHD, and cardiac/obstetric anesthesia experts, is recommended. A multidisciplinary approach and targeted PAH therapy may result in improved pregnancy outcomes [<a href="#rid19">19,30</a>]; in one series, pregnancy outcome was most favorable in long-term responders to calcium channel blockers [<a href="#rid31">31</a>].</p><p>If the patient desires to continue the pregnancy, the following steps should be followed to try to ensure the best possible outcome for the mother and child [<a href="#rid32">32,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral</strong> – Patients are referred to a center with PH-CHD and maternal-fetal medicine expertise, as these centers provide the optimal combination of clinical expertise, facilities for advanced diagnosis and therapy, structured care, and access to new and evolving therapies. Patients with PH-CHD are the highest-risk patients with preexisting cardiovascular disease during pregnancy. Care of patients with PH-CHD includes management of issues related to the intracardiac shunt, cyanotic heart disease, PH, and Eisenmenger syndrome. (See  <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">"Medical management of cyanotic congenital heart disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: General management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/139770.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: Disease-specific management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for VTE risk</strong> – Evaluation is performed during early pregnancy to classify the risk of venous thromboembolism (VTE) and determine whether prophylaxis against VTE is indicated [<a href="#rid19">19</a>]. A careful assessment of maternal and fetal risks and benefits is required since the risk of exacerbating intrinsic hemostatic defects with prophylactic heparin therapy may outweigh any theoretical benefits, and the care of each patient requires careful review and discussion [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">"Medical management of cyanotic congenital heart disease in adults", section on 'Thromboembolism'</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p></p><p class="bulletIndent1">All patients require vigilant clinical surveillance for symptoms and signs of VTE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication adjustment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinue any endothelin receptor antagonists (eg, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>) and guanylate cyclase stimulants (<a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a>). These medications are contraindicated during pregnancy and in women who may become pregnant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient is on a long-acting calcium channel blocker, this therapy is continued. As discussed separately, most patients with PH-CHD are not candidates for calcium channel blocker therapy. (See  <a class="medical medical_review" href="/z/d/html/139770.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: Disease-specific management", section on 'Calcium channel blocker not used'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with World Health Organization (WHO) functional class II or III symptoms  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 3</a>), continue or start a phosphodiesterase-5 inhibitor (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients judged to be at risk of clinical deterioration (ie, WHO functional class III with progressive disease or right heart dysfunction or WHO class IV symptoms  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 3</a>)), <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> is an option. For patients already treated with prostacyclin pathway agonist, such therapy is generally continued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxygen</strong> – Continue oxygen therapy, if indicated. (See  <a class="medical medical_review" href="/z/d/html/119400.html" rel="external">"Pulmonary hypertension in adults with congenital heart disease: General management and prognosis", section on 'General approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – This should include at least monthly visits with maternal-fetal medicine and cardiology caregivers with echocardiograms and B-type natriuretic peptide levels to screen for right ventricular decompensation and right heart failure. Weekly or biweekly visits may be required during the third trimester [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of inpatient care</strong> – Early hospitalization (eg, at 20 weeks) for close clinical monitoring may be required for some patients [<a href="#rid12">12,36</a>].</p><p></p><p class="headingAnchor" id="H828723669"><span class="h2">Delivery</span><span class="headingEndMark"> — </span>The optimum timing and mode of delivery in this setting is controversial. The multidisciplinary team should prepare a detailed delivery plan including preparation for postpartum intensive care and circulatory support, if needed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – Many experts favor an individualized approach with delivery performed at 34 to 37 weeks of gestation, with later delivery favored when the woman and fetus are stable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mode</strong> – The mode of delivery is individualized, with obstetric principles applied to select the least hemodynamically stressful mode of delivery unless there is a specific overriding obstetric indication for cesarean delivery. Options include controlled vaginal delivery with early epidural analgesia and vacuum extraction or low forceps delivery to minimize expulsive efforts. Some experts favor scheduled cesarean delivery with epidural anesthesia at 34 weeks of gestation. Regional anesthesia is generally favored over general anesthesia in this setting [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring </strong>– Pulmonary artery catheter monitoring is avoided because of general lack of benefit in this setting and high risk for hemorrhagic and other complications [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical support </strong>– Supplemental oxygen should be given during delivery because of its beneficial effects on pulmonary vascular resistance and shunt flow [<a href="#rid12">12,38</a>]. Peripartum hypotension should be treated promptly with fluids and pressors to prevent an increase in the right-to-left shunt.</p><p></p><p class="bulletIndent1">Circulatory support options such as extracorporeal membrane oxygenation should be available in the event of peripartum hemodynamic collapse. (See  <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/14184.html" rel="external">"Sudden cardiac arrest and death in pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H2851199580"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122280.html" rel="external">"Society guideline links: Congenital heart disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118887.html" rel="external">"Society guideline links: Management of cardiovascular diseases during pregnancy"</a>.)</p><p class="headingAnchor" id="H1729409023"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of pregnancy</strong> – Pregnancy in patients with pulmonary hypertension-congenital heart disease (PH-CHD) is associated with high maternal and fetal risks, with the highest risks seen in patients with Eisenmenger syndrome. (See <a class="local">'Risk of pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maternal risk</strong> – The reported maternal mortality with Eisenmenger syndrome appears to be declining but remains above 10 percent. The mortality risk cannot be reliably predicted and death can occur even in patients with few symptoms prior to pregnancy. Causes of death include refractory right heart failure, pulmonary hypertensive crisis, thromboembolism, volume depletion, and preeclampsia. (See <a class="local">'Maternal issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal risk </strong>–<strong> </strong>In the setting of Eisenmenger syndrome, spontaneous abortion occurs in 20 to 40 percent of pregnancies, at least 50 percent of infants are born prematurely, at least 20 to 30 percent of infants born have intrauterine growth retardation, and perinatal mortality has ranged from 7 to 28 percent. An additional concern is the elevated risk of recurrent CHD in the fetus. (See <a class="local">'Fetal issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraception</strong> – Safe and effective contraception options are crucial for patients with PH-CHD given the very high risks of pregnancy. Options for contraception include male vasectomy, long-acting reversible contraception (LARC), and female sterilization. (See <a class="local">'Contraception methods'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling if pregnancy occurs</strong> – Women with PH-CHD who become pregnant should receive individualized counseling regarding maternal and fetal risks from cardiovascular and maternal-fetal medicine caregivers with expertise in the management of PH-CHD. The earliest possible pregnancy termination should be discussed, as termination may be life-saving for the mother. (See <a class="local">'Counseling if pregnancy occurs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management during pregnancy</strong> – When a patient elects to continue pregnancy, comprehensive multidisciplinary care, including (at a minimum) maternal-fetal medicine, PH-CHD experts, and cardiac/obstetric anesthesia experts, is recommended. A multidisciplinary approach and targeted pulmonary arterial hypertension (PAH) therapy may result in improved pregnancy outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery</strong> – The optimum timing and mode of delivery in this setting is controversial. The multidisciplinary team should prepare a detailed delivery plan including preparation for postpartum intensive care and circulatory support, if needed.</p><p></p><p class="bulletIndent1">Many experts favor an individualized approach with delivery performed at 34 to 37 weeks of gestation, with later delivery favored when the woman and fetus are stable. Options include controlled vaginal delivery with early epidural anesthesia. (See <a class="local">'Delivery'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58:538.</a></li><li><a class="nounderline abstract_t">van Riel AC, Schuuring MJ, van Hessen ID, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol 2014; 174:299.</a></li><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D42.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc 2023; 12:e029024.</a></li><li><a class="nounderline abstract_t">Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42:563.</a></li><li><a class="nounderline abstract_t">Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16:19.</a></li><li><a class="nounderline abstract_t">Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002; 89:34.</a></li><li><a class="nounderline abstract_t">Li Q, Dimopoulos K, Liu T, et al. Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease. Eur J Prev Cardiol 2019; 26:1067.</a></li><li><a class="nounderline abstract_t">Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30:256.</a></li><li><a class="nounderline abstract_t">Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128:745.</a></li><li><a class="nounderline abstract_t">Gleicher N, Midwall J, Hochberger D, Jaffin H. Eisenmenger's syndrome and pregnancy. Obstet Gynecol Surv 1979; 34:721.</a></li><li><a class="nounderline abstract_t">Yentis SM, Steer PJ, Plaat F. Eisenmenger's syndrome in pregnancy: maternal and fetal mortality in the 1990s. Br J Obstet Gynaecol 1998; 105:921.</a></li><li><a class="nounderline abstract_t">Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31:1650.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.</a></li><li><a class="nounderline abstract_t">Liu Y, Li Y, Zhang J, et al. Maternal and fetal outcomes of pregnant women with pulmonary arterial hypertension associated with congenital heart disease in Beijing, China: A retrospective study. Pulm Circ 2022; 12:e12079.</a></li><li><a class="nounderline abstract_t">Sliwa K, Baris L, Sinning C, et al. Pregnant Women With Uncorrected Congenital Heart Disease: Heart Failure and Mortality. JACC Heart Fail 2020; 8:100.</a></li><li><a class="nounderline abstract_t">Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39:3165.</a></li><li><a class="nounderline abstract_t">Brunner N, de Jesus Perez VA, Richter A, et al. Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery. Pulm Circ 2014; 4:10.</a></li><li><a class="nounderline abstract_t">Ladouceur M, Benoit L, Radojevic J, et al. Pregnancy outcomes in patients with pulmonary arterial hypertension associated with congenital heart disease. Heart 2017; 103:287.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li class="breakAll">Hou MY, Roncari D. Permanent contraception. In: Contraceptive Technology, 21st, Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman AB, Aiken AR, Marrazzo JM, Kowal D (Eds), Ayer Company Publishers Inc, New York, NY 2018. p.461.</li><li class="breakAll">Table 26-1 Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use. In: Contraceptive Technology, 21st, Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman AB, Aiken AR, Marrazzo JM, Kowal D (Eds), Ayer Company Publishers Inc, New York, NY 2018. p.844.</li><li class="breakAll">Nexplanon- etonogestrel implant. US Food and Drug Administration (FDA) approved product information. Revised October 2018. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b03a3917-9a65-45c2-bbbb-871da858ef34 (Accessed on April 16, 2019).</li><li class="breakAll">Nelson AL, Sokol DC, Grentzer J. Contraceptive Implant. In: Contraceptive Technology, 21st, Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman AG, Aiken AR, Marrazo JM (Eds), Ayer Company Publishers, Inc., New York, NY 2018. p.139.</li><li><a class="nounderline abstract_t">Chi I, Wilkens LR, Siemens AJ, Potts M. Rare events occurring at insertion of an intrauterine device--a review of an international experience. Adv Contracept 1987; 3:49.</a></li><li><a class="nounderline abstract_t">Hankins GD, Berryman GK, Scott RT Jr, Hood D. Maternal arterial desaturation with 15-methyl prostaglandin F2 alpha for uterine atony. Obstet Gynecol 1988; 72:367.</a></li><li><a class="nounderline abstract_t">Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.</a></li><li><a class="nounderline abstract_t">Kiely DG, Condliffe R, Webster V, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 2010; 117:565.</a></li><li><a class="nounderline abstract_t">Jaïs X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012; 40:881.</a></li><li><a class="nounderline abstract_t">McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65:1976.</a></li><li><a class="nounderline abstract_t">Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005; 102:1133.</a></li><li><a class="nounderline abstract_t">Pitts JA, Crosby WM, Basta LL. Eisenmenger's syndrome in pregnancy: does heparin prophylaxis improve the maternal mortality rate? Am Heart J 1977; 93:321.</a></li><li><a class="nounderline abstract_t">Kahn ML. Eisenmenger's syndrome in pregnancy. N Engl J Med 1993; 329:887.</a></li><li><a class="nounderline abstract_t">Kelion AD, Webb TP, Gardner MA, et al. The warm-up effect protects against ischemic left ventricular dysfunction in patients with angina. J Am Coll Cardiol 2001; 37:705.</a></li><li><a class="nounderline abstract_t">Robinson S. Pulmonary artery catheters in Eisenmenger's syndrome: many risks, few benefits. Anesthesiology 1983; 58:588.</a></li><li><a class="nounderline abstract_t">Midwall J, Jaffin H, Herman MV, Kupersmith J. Shunt flow and pulmonary hemodynamics during labor and delivery in the Eisenmenger syndrome. Am J Cardiol 1978; 42:299.</a></li></ol></div><div id="topicVersionRevision">Topic 139887 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777753" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794056" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355641" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Definitions and diagnosis of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37026538" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860028" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2020 ESC Guidelines for the management of adult congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654195" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The remarkable right ventricle of patients with Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779519" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30971116" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147605" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9556469" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Eisenmenger syndrome in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/503376" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Eisenmenger's syndrome and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746388" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Eisenmenger's syndrome in pregnancy: maternal and fetal mortality in the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626847" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572244" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcome of pregnancy in women with congenital heart disease: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35514772" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Maternal and fetal outcomes of pregnant women with pulmonary arterial hypertension associated with congenital heart disease in Beijing, China: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31511192" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pregnant Women With Uncorrected Congenital Heart Disease: Heart Failure and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165544" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006417" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27511447" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pregnancy outcomes in patients with pulmonary arterial hypertension associated with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3630819" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rare events occurring at insertion of an intrauterine device--a review of an international experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261408" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Maternal arterial desaturation with 15-methyl prostaglandin F2 alpha for uterine atony.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997169" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20374595" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282544" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pregnancy outcomes in pulmonary arterial hypertension in the modern management era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25953750" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Management of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915025" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/300214" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Eisenmenger's syndrome in pregnancy: does heparin prophylaxis improve the maternal mortality rate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355757" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Eisenmenger's syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693740" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The warm-up effect protects against ischemic left ventricular dysfunction in patients with angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859598" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulmonary artery catheters in Eisenmenger's syndrome: many risks, few benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/150787" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Shunt flow and pulmonary hemodynamics during labor and delivery in the Eisenmenger syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
